For your practice

Grifols is committed to partnering with healthcare providers, providing the alpha-1 healthcare community with the resources needed to make a difference in patients' lives.

Order FREE Grifols AlphaKit™ test kits now >
We've made it simple for you to receive FREE Grifols AlphaKit test kits.

Download, complete, and fax the enrollment form >

  • PROLASTIN®-C (alpha1-proteinase inhibitor [human]) is ONLY available through the PROLASTIN DIRECT program
  • It takes one form to start your patients on PROLASTIN-C and connect them to the comprehensive personalized support of the PROLASTIN DIRECT program
  • Call PROLASTIN DIRECT at 1-800-305-7881 with questions

Annotated enrollment form

  • Field-by-field tips to avoid potential errors and ensure successful submission of your enrollment form

Request a representative >

Learn more from a Grifols alpha-1 specialty representative in your area.

Downloadable Alpha-1 Foundation Resources

The following tools from the Alpha-1 Foundation help people with alpha-1 better understand and manage their condition.


Video resources for HCPs and patients

Learn more about alpha-1.
Watch the MOA video>

Learn more about the comprehensive, personalized alpha-1 support for patients and physicians and their practices, available ONLY through the PROLASTIN DIRECT program.
View the full PROLASTIN DIRECT Story>

Partners in patient care

AlphaNet >

Alpha-1 Foundation >

You will need Adobe® Reader® installed on your computer to view PDFs. You can download a copy of Adobe Reader by clicking the link below.

Get Adobe Reader

Adobe and Adobe Reader are registered trademarks of Adobe Systems Incorporated.

Have your patients seen the PROLASTIN DIRECT Story?

PROLASTIN®-C (alpha1-proteinase inhibitor [human]) is indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1-PI (alpha1-antitrypsin deficiency).

The effect of augmentation therapy with any alpha1-proteinase inhibitor (alpha1-PI), including PROLASTIN-C, on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been conclusively demonstrated in randomized, controlled clinical trials. Clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with PROLASTIN-C are not available.

PROLASTIN-C is not indicated as therapy for lung disease in patients in whom severe alpha1-PI deficiency has not been established.

PROLASTIN-C is contraindicated in IgA-deficient patients with antibodies against IgA due to the risk of severe hypersensitivity and in patients with a history of anaphylaxis or other severe systemic reactions to alpha1-PI.

Hypersensitivity reactions, including anaphylaxis, may occur. Monitor vital signs and observe the patient carefully throughout the infusion. Should hypersensitivity symptoms be observed, promptly stop infusion and begin appropriate therapy. Have epinephrine and other appropriate therapy available for the treatment of any acute anaphylactic or anaphylactoid reaction.

PROLASTIN-C may contain trace amounts of IgA. Patients with known antibodies to IgA, which can be present in patients with selective or severe IgA deficiency, have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions.

The most common drug-related adverse reaction observed at a rate of >5% in subjects receiving PROLASTIN-C was upper respiratory tract infection. The most serious adverse reaction observed during clinical trials with PROLASTIN-C was an abdominal and extremity rash in 1 subject.

Because PROLASTIN-C is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens.

Please click here for full Prescribing Information for PROLASTIN-C.


  1. Data on file, PROLASTIN DIRECT program.